Sagimet Biosciences Inc. (SGMT), Tuesday said that the U.S. Food and Drug Administration or FDA has given clearance to its investigational new drug (IND) application for TVB-3567 for the treatment of acne.
The company plans to initiate a Phase 1 study of TVB-3567 in 2025.
For comments and feedback: editorial@rttnews.com